Advertisement
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease

Andrew J. Hirsh, Jim Zhang, Andra Zamurs, Jacquelyn Fleegle, William R. Thelin, Ray A. Caldwell, Juan R. Sabater, William M. Abraham, Mark Donowitz, Boyoung Cha, Kevin B. Johnson, Judith A. St. George, M. Ross Johnson and Richard C. Boucher
Journal of Pharmacology and Experimental Therapeutics April 2008, 325 (1) 77-88; DOI: https://doi.org/10.1124/jpet.107.130443

Article Information

vol. 325 no. 1 77-88
DOI 
https://doi.org/10.1124/jpet.107.130443
PubMed 
18218832
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received August 17, 2007
  • Accepted January 23, 2008
  • Published online March 17, 2008.

Article Versions

Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Andrew J. Hirsh,
  2. Jim Zhang,
  3. Andra Zamurs,
  4. Jacquelyn Fleegle,
  5. William R. Thelin,
  6. Ray A. Caldwell,
  7. Juan R. Sabater,
  8. William M. Abraham,
  9. Mark Donowitz,
  10. Boyoung Cha,
  11. Kevin B. Johnson,
  12. Judith A. St. George,
  13. M. Ross Johnson and
  14. Richard C. Boucher
  1. Parion Sciences Inc., Durham, North Carolina (A.J.H., A.Z., J.F., K.B.J., J.A.S.G., M.R.J.); Albany Molecular Research Inc., Albany, New York (J.Z.); Cystic Fibrosis/Pulmonary Research and Treatment Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (W.R.T., R.A.C., R.C.B.); Division of Pulmonary and Critical Care Medicine, University of Miami at Mount Sinai Medical Center, Miami Beach, Florida (J.R.S., W.M.A.); and Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland (M.D., B.C.)
  1. Address correspondence to:
    Dr. Andrew J. Hirsh, Parion Sciences Inc., 2525 Meridian Pkwy., Suite 260, Durham, NC 27713. E-mail: ajhirsh{at}parion.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: January 2008 to January 2023

AbstractFullPdf
Jan 2008180136
Feb 2008350137
Mar 20087929130
Apr 2008683363
May 2008422551
Jun 2008521532
Jul 2008482343
Aug 2008351729
Sep 2008382623
Oct 2008301526
Nov 2008382033
Dec 200835918
Jan 200930916
Feb 2009311421
Mar 2009311728
Apr 2009283238
May 2009252526
Jun 2009363533
Jul 2009173017
Aug 2009282720
Sep 2009223023
Oct 2009253227
Nov 2009362323
Dec 2009271417
Jan 2010332016
Feb 2010311519
Mar 2010292318
Apr 2010343516
May 2010261317
Jun 201022159
Jul 201012199
Aug 2010222616
Sep 2010331913
Oct 2010331717
Nov 2010281613
Dec 2010172515
Jan 2011272916
Feb 2011151629
Mar 2011322625
Apr 2011192119
May 2011181719
Jun 2011282023
Jul 2011172328
Aug 2011201620
Sep 2011192629
Oct 2011233323
Nov 2011293528
Dec 2011212534
Jan 2012312427
Feb 2012261432
Mar 2012282217
Apr 2012391920
May 2012263127
Jun 2012231333
Jul 2012242524
Aug 2012291821
Sep 2012232229
Oct 2012302433
Nov 2012261724
Dec 2012151522
Jan 2013222520
Feb 2013352325
Mar 2013202121
Apr 2013231825
May 2013312017
Jun 2013182119
Jul 2013231016
Aug 2013171011
Sep 2013171927
Oct 2013142418
Nov 2013132015
Dec 2013183912
Jan 2014112423
Feb 2014132511
Mar 201416157
Apr 2014221712
May 201412711
Jun 201491010
Jul 2014271416
Aug 201410146
Sep 2014162122
Oct 2014121214
Nov 2014201718
Dec 201416127
Jan 2015161912
Feb 2015151812
Mar 2015102210
Apr 2015141222
May 20159236
Jun 2015153525
Jul 2015131420
Aug 2015261917
Sep 2015192211
Oct 2015141211
Nov 201516108
Dec 201522117
Jan 2016181716
Feb 201612147
Mar 201636912
Apr 2016121811
May 20166710
Jun 2016252023
Jul 2016252332
Aug 2016252630
Sep 2016254025
Oct 201612588
Nov 2016922311
Dec 201633108
Jan 2017119725
Feb 2017116128
Mar 2017123821
Apr 2017112528
May 2017511257
Jun 2017112634
Jul 201703918
Aug 20170359
Sep 201713310
Oct 20171366
Nov 20171287
Dec 20171464
Jan 201814213
Feb 20182213
Mar 201831618
Apr 201822611
May 201803112
Jun 201832810
Jul 20180269
Aug 20180203
Sep 201803419
Oct 201813910
Nov 20180376
Dec 20181999
Jan 201927310
Feb 20192249
Mar 2019933
Apr 20192833
May 20191142
Jun 201912213
Jul 201922612
Aug 201926175
Sep 2019456914
Oct 20192583
Nov 20192335
Dec 20192700
Jan 2020911
Feb 20202341
Mar 20202720
Apr 20202124
May 20201602
Jun 20201001
Jul 20201211
Aug 2020800
Sep 2020734
Oct 20202914
Nov 20202314
Dec 20201914
Jan 20212459
Feb 20212025
Mar 20212759
Apr 20211752
May 20211552
Jun 20211746
Jul 20211013
Aug 20211442
Sep 2021920
Oct 20211931
Nov 20212425
Dec 20212722
Jan 20222628
Feb 20221521
Mar 20222122
Apr 20221514
May 20221912
Jun 20222010
Jul 20221922
Aug 2022926
Sep 20221554
Oct 20221443
Nov 20223244
Dec 20222353
Jan 20232874

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease

Andrew J. Hirsh, Jim Zhang, Andra Zamurs, Jacquelyn Fleegle, William R. Thelin, Ray A. Caldwell, Juan R. Sabater, William M. Abraham, Mark Donowitz, Boyoung Cha, Kevin B. Johnson, Judith A. St. George, M. Ross Johnson and Richard C. Boucher
Journal of Pharmacology and Experimental Therapeutics April 1, 2008, 325 (1) 77-88; DOI: https://doi.org/10.1124/jpet.107.130443
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement